Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma - Summary - MDSpire

Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma

  • By

  • Malin Hultcrantz

  • Hani Hassoun

  • Neha Korde

  • Kylee MacLachlan

  • Sham Mailankody

  • Dhwani Patel

  • Urvi A. Shah

  • Carlyn Rose Tan

  • David J. Chung

  • Oscar B. Lahoud

  • Heather J. Landau

  • Michael Scordo

  • Gunjan L. Shah

  • Sergio A. Giralt

  • Matthew J. Pianko

  • Miranda Burge

  • Kelly Barnett

  • Meghan Salcedo

  • Julia Caple

  • Linh Tran

  • Jenna Blaslov

  • Tala Shekarkhand

  • Selena Hamid

  • David Nemirovsky

  • Andriy Derkach

  • Oluwatobi Arisa

  • Cody J. Peer

  • William D. Figg

  • Saad Z. Usmani

  • Ola Landgren

  • Alexander M. Lesokhin

  • September 19, 2024

  • 0 min

Share

Objective:

To evaluate the safety and efficacy of colesevelam in treating lenalidomide-associated diarrhea in multiple myeloma patients.

Key Findings:
  • Colesevelam was effective, with 88% of patients responding and 68% achieving complete resolution of diarrhea, despite limited effects from standard anti-diarrheal medications.
  • Pharmacokinetics of lenalidomide were evaluated, but the interaction with colesevelam was not previously studied.
Interpretation:

Colesevelam appears to be a promising treatment for managing diarrhea associated with lenalidomide in multiple myeloma patients, potentially improving their quality of life and treatment adherence.

Limitations:
  • Small sample size of 25 patients.
  • Single-arm design limits comparison to control groups.
Conclusion:

Colesevelam is a highly effective treatment for lenalidomide-associated diarrhea, with significant improvements observed in the majority of patients.

Original Source(s)

Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma

  • by Malin Hultcrantz, Hani Hassoun, Neha Korde, Kylee MacLachlan, Sham Mailankody, Dhwani Patel, Urvi A. Shah, Carlyn Rose Tan, David J. Chung, Oscar B. Lahoud, Heather J. Landau, Michael Scordo, Gunjan L. Shah, Sergio A. Giralt, Matthew J. Pianko, Miranda Burge, Kelly Barnett, Meghan Salcedo, Julia Caple, Linh Tran, Jenna Blaslov, Tala Shekarkhand, Selena Hamid, David Nemirovsky, Andriy Derkach, Oluwatobi Arisa, Cody J. Peer, William D. Figg, Saad Z. Usmani, Ola Landgren, Alexander M. Lesokhin

  • September 19, 2024

Related Content

Editorial: A new perspective on the importance of dendritic cells in cancer immunity: from bench to patient’s bedside

Financial toxicity as logistical and relational burden across the lifespan during autologous transplant preparation

Not all plasma cells are made equal: well-hidden layers of heterogeneity